Optimal IFN-γ Priming and Therapeutic Efficacy of 3D-Cultured Human Umbilical Cord-Derived Mesenchymal Stem Cells

3D培养的人脐带间充质干细胞的最佳IFN-γ启动和治疗效果

阅读:2

Abstract

BACKGROUND: This study focuses on addressing the challenges associated with temporomandibular joint osteoarthritis (TMJOA), a condition currently considered incurable. Osteoarthritis (OA) is a degenerative disease of cartilage and tissues that affects the temporomandibular joint (TMJ). The potential of interferon-γ (IFN-γ)-primed three-dimensional (3D) spheroids of umbilical cord-derived mesenchymal stem cells (UC-MSCs) was investigated as a therapeutic intervention for TMJOA. This research aims to confirm that enhanced 3D UC-MSC spheroids are more effective than their two-dimensional (2D) counterparts. METHODS: Effective conditions for IFN-γ-primed 3D spheroids in the treatment of temporomandibular joint osteoarthritis (TMJOA) were determined. The therapeutic potential was confirmed by co-culturing with synovium-derived cells from patients with temporomandibular disorder (TMD-SDCs). The therapeutic efficacy was confirmed by injecting IFN-γ-primed 3D spheroids into rats with TMJOA. RESULTS: Co-culturing TMD-SDCs with IFN-γ-primed 3D UC-MSC spheroids resulted in significantly improved regenerative and anti-inflammatory effects compared to co-cultures with 2D UC-MSCs. Validation in TMJOA rats further supported the promising effects of IFN-γ-primed 3D spheroids of UC-MSCs. The 3D spheroids group showed rapid recovery based on micro-computed tomography images, histology images, and pain response. CONCLUSION: MSCs were enhanced using cytokine priming and 3D spheroid culture. We successfully established the effective priming conditions for the therapeutic application of IFN-γ-primed 3D spheroids. The findings suggest their potential benefits in the treatment of TMJOA which is currently incurable and inform further advancements in regenerative medicine.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。